The future of heart/skeletal muscle therapy in DMD will likely require a combination of approaches to achieve optimal outcomes, including a therapeutic approach to correct the genetic defect and target the secondary effects caused by the lack of dystrophin. This evidence concerns the gene DMD and Duchenne muscular dystrophy.